The SRD (CHD5) Deletion probe consists of a 210kb red probe spanning the SRD (CHD5) gene region. The 1qter probe in green acts as a control for chromosome 1.
The 1p36 region is frequently deleted in a broad range of human cancers1. The Chromodomain Helicase DNA binding domain 5 (CHD5) gene acts as a tumour suppressor at 1p36.31 and is frequently deleted in human gliomas1, leukaemias/lymphomas2 and neuroblastomas3.
Deletion of the short arm of chromosome 1 is one of the most characteristic genetic changes in neuroblastoma, a tumour of the sympathetic nervous system. This is the most common childhood solid extracranial tumour, accounting for around 8%-10% of childhood cancers and 15% of childhood cancer deaths4.
The CHD5 gene has been characterised as the lead tumour suppressor candidate from the 1p36 smallest region of consistent deletion (SRD) region in neuroblastoma5.
It was very important for us to have more consistent results with our probes — easy-to-read bright signals and a range of vial sizes, which is much more cost-effective. It also was critical to upgrade our pretreatment kit to expedite the analysis of FFPE samples. We can now complete the process in about 90 minutes.
Janet Cowan, PhD
Director of the Cytogenetics Laboratory, Tufts Medical Center, USA